A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00788463|
Recruitment Status : Completed
First Posted : November 11, 2008
Last Update Posted : August 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|Nasal Polyps||Drug: Intranasal Beclomethasone aerosol Drug: Intranasal Beclomethasone spray||Phase 2|
Aqueous and aerosol delivery of intranasal corticosteroids has never been directly compared previously in patients with nasal polyps and it is unknown whether one is superior.
This objective of this study is to compare the efficacy of intranasal beclomethasone by two different delivery systems, aerosol and aqueous spray in patients with nasal polyps. Primary endpoint is the difference in the overall quality of life as measured by the Rhinitis Quality of Life Questionnaire. The secondary endpoint is the change in Nasal Airflow Resistance as measured by rhinomanometry.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps|
|Actual Study Start Date :||November 23, 2006|
|Actual Primary Completion Date :||March 30, 2009|
|Actual Study Completion Date :||November 30, 2011|
Drug: Intranasal Beclomethasone aerosol
Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
Other Name: QVAR
|Active Comparator: Spray||
Drug: Intranasal Beclomethasone spray
Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
- Difference in overall quality of life as measured by the Rhinitis Quality of Life Questionnaire [ Time Frame: 0, 1, 3, 6 months ]
- Difference in Nasal Airflow Resistance as measured an anterior rhinomanometry [ Time Frame: 0, 1, 3, 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00788463
|Allergy Clinic, London Health Sciences Centre|
|London, Ontario, Canada, N6A 4G5|
|Principal Investigator:||Jorge A Mazza, MD||University of Western Ontario, Canada|